175 related articles for article (PubMed ID: 7579007)
1. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
[TBL] [Abstract][Full Text] [Related]
2. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
3. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
4. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
5. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
9. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
[TBL] [Abstract][Full Text] [Related]
10. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
[TBL] [Abstract][Full Text] [Related]
13. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
Baba M; Kimura K; Suda T; Yagihashi S;
J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
[No Abstract] [Full Text] [Related]
14. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
15. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
[No Abstract] [Full Text] [Related]
16. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR
Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
[TBL] [Abstract][Full Text] [Related]
18. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
Schemmel KE; Padiyara RS; D'Souza JJ
J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
[TBL] [Abstract][Full Text] [Related]
19. Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.
Kuriya N; Miyake S; Yokota A; Yamaguchi Y; Nakanishi T; Takahashi A; Ueda Y; Mori T; Akiguchi I; Toyama K
J Med Assoc Thai; 1987 Mar; 70 Suppl 2():168-72. PubMed ID: 3110345
[No Abstract] [Full Text] [Related]
20. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
